Together, our results present a new strategy to follow the dysregulation of A3A in tumors, which will provide new opportunities to investigate the role of A3A in tumor evolution and to target A3A-induced vulnerabilities in cancer therapy. The gene discussed is APOBEC3A; the disease is cancer.